Jeevan on for Les Sulewski's questions to CorMedix Inc (CRMD) leadership • Q4 2024
Question
Jeevan, on behalf of Les Sulewski, asked if the recently announced hemodialysis blood line shortages would impact DefenCath utilization and requested an update on manufacturing capacity and the ability to fill outstanding purchase orders.
Answer
Executive Elizabeth Masson-Hurlburt stated the blood line shortage is unlikely to impact DefenCath use due to available alternative manufacturers. Executive Joseph Todisco confirmed there are no manufacturing constraints, noting CorMedix has over a year's worth of finished product on hand at the current run rate and can easily fill all orders.